|
Indian Pediatr 2016;53: 732-734 |
|
Lysinuric Protein
Intolerance Presenting with Recurrent Hyperammonemic
Encephalopathy
|
Sunita Bijarnia-Mahay, *Vivek
Jain, *Rajiv
Kumar Bansal, #Gummadi
Maheshwar Reddy and ‡Johannes
Häberle
From Institute of Medical Genetics and Genomics, Sir
Ganga Ram Hospital, New Delhi, *Department of Pediatrics, Santokba
Durlabhji Memorial Hospital, Jaipur; and Department of Biochemical
Genetics, Sandor Lifesciences Pvt. Ltd., Hyderabad; India; and ‡Division
of Metabolism, University Children’s Hospital Zurich, Switzerland
Correspondence to: Dr Sunita Bijarnia-Mahay,
Senior Consultant, Institute of Medical Genetics and Genomics, Sir Ganga
Ram Hospital, Rajinder Nagar, New Delhi 110 060.
Email: [email protected]
Received: September 29, 2015;
Initial review: December 26, 2015;
Accepted: March 28, 2016.
|
Background: Lysinuric protein intolerance is an inherited disorder
of transport of cationic amino acids, causing amino aciduria. Case
characteristics: A 3-year-old boy with 12 month history of episodic
change in behavior (decreased sleep, poor interaction), stunted growth
and hyperammonemia. Outcome: Genetic analysis revealed a
homozygous mutation, c.158C>T (p.Ser53Leu) in exon 1 of SLC7A7
gene.With appropriate management of hyperammonemia episodes, his
neurodevelopmental outcome is normal. Message: Lysinusic protein
intolerance is a potentially treatable disorder and should not to be
missed.
Keywords: Behavioral problems, Neurometabolic disorder, Urea
cycle disorder.
|
Lysinuric protein intolerance (MIM #222700) (LPI)
is an autosomal recessive inborn error of metabolism caused by mutations
in the SLC7A7 gene disrupting absorption and reabsorption of
cationic amino acids, arginine, lysine and ornithine, across the
intestinal and renal tubular membranes, respectively [1]. Infants with
this disorder usually present after weaning with recurrent diarrhea,
failure to thrive and episodes of stupor. As the disease can show
varying multisystem presentations, it is likely to be misdiagnosed [2].
Pulmonary alveolar proteinosis, renal disease, hemophagocytic
lymphohistiocytosis, osteo-porosis and various auto-immune and
immunodeficiency disorders have been described in patients with LPI
[2,3]. Recurrent hyperammonemic encephalopathy occurs frequently, and is
due to deficiency of arginine and ornithine causing disruption of the
urea cycle [3].
We report a child with LPI who presented with
recurrent episodes of encephalopathy due to hyper-ammonemia.
Case Report
A 3-and-a-half-year-old boy, born to a consanguineous
couple, presented with episodes of difficulty in falling to sleep
lasting several days, excessive crying and decreased oral intake over
the last 18 months. This episodic change in behavior usually followed
acute illness, especially gastroenteritis, though most episodes never
required hospital admission. Except these episodes, the child was well,
with the exception that parents had noted gradual regression of speech
with poor eye contact and interaction with family members. This episodic
mild encephalopathy was mistaken for epilepsy and treatment given.
However, multiple anti-convulsants proved ineffective.
On examination, his height and weight were low
-Weight 10.5 kg (<1 st
centile), height 90 cm (on 3rd
centile) and head circumference of 47.5 cm (3rd
centile) according to WHO charts. Child was pale and had mild
hepatosplenomegaly. He was also restless, with limited speech and poor
eye contact. Unsteadiness of gait was also noted. Routine investigations
of blood counts, electrolytes, blood gas analysis, liver and renal
functions did not show any abnormality except mild anemia (hemoglobin
11.2 g/dL) (Table I). His plasma ammonia level was 840
µmol/L (normal range < 50); serum ferritin and LDH were also raised.
Amino acids analysis revealed decreased levels of lysine, arginine and
ornithine in plasma, and marked elevation of the same amino acids in the
urine. Urine organic acids analysis by GC-MS (Gas Chromatography-Mass
Spectrometry) demonstrated elevated levels of orotic acid (460-fold).
EEG showed mild diffuse slowing of electrical activity, and MRI of brain
revealed subtle symmetrical periventricular T2 hyper-intensities. Based
on the finding of hyperammonemia along with unusual high excretion of
cationic amino acids (lysine, arginine and ornithine) in urine, and
deficient levels in plasma, a diagnosis of LPI was made.
TABLE I Laboratory Parameters in the Patient
Investigations |
Result |
ALT (SGPT) |
30 IU/L(0-60) |
ALP |
513 IU/L(250-770) |
Blood urea |
6 mg/dL, |
Serum Creatinine |
0.3 mg/dL |
Serum Ferritin ng/mL |
572 (17.9 - 464) |
LDH |
2254 U/L (normal 313-464) |
Plasma amino acids (nmol/mL) |
Lysine |
16.7 (48-284) |
Ornithine undetectable Arginine |
12.8 (10-140) |
Urine amino acids |
(10-163) (nmol/mg of creatinine) |
Lysine |
3912 (34-894) |
Arginine |
292.5 (7-133) |
Ornithine |
32.8 (2-91) |
Mutation analysis of SLC7A7 gene using
sequencing showed homozygous, previously reported mutation, c.158C>T
(p.Ser53Leu) in exon 1. Computational analysis of the variation revealed
likely pathogenic by Mutationtaster, Polyphen 2, SIFT and Provean
softwares.
After start of sodium benzoate, L-carnitine, low dose
citrulline supplements and a protein-restricted diet, the child showed a
marked improvement in symptoms. On follow-up at two years after
diagnosis, his episodic behavioral symptoms had completely resolved. His
interaction with parents and peer group was normal, there was good
eye-to-eye contact and resolution of hyperactivity. He was in grade one
at school, with no concerns about his academic performance. His physical
growth was low (3rd centile), but tracking along the same centile,
splenomegaly had resolved and mild hepatomegaly was present. Since start
of specific treatment, he has had two further episodes of intercurrent
illness, which could be managed with extra non-protein calories and
sodium benzoate averting signs of encephalopathy. The most recent plasma
amino acids analysis showed normal arginine, but low lysine and
ornithine. Urinalysis for proteinuria and a chest radiograph showed
normal findings.
Discussion
LPI is characterized by a complex pathophysiology
extending beyond merely a disruption of ureagenesis [3,4]. A defect in
the SLC7A7 gene is responsible for this disorder. Although more
than 50 mutations have been detected in patients across the world, none
has been described in Indian patient.
This unique multi-systemic disorder occurs due to
defective intestinal absorption and renal reabsorption of amino acids –
lysine, arginine and ornithine, leading to low levels of these amino
acids in plasma and high levels in urine. While these cationic amino
acids are essential for various biochemical pathways and bodily
functions, the urea cycle is affected secondarily due to depletion of
its metabolites, arginine and ornithine, leading to hyperammonemia.
Other complications are thought to be related to the derangement in
arginine metabolism [2]. Excess intracellular arginine, because of
trapping (due to block in transport) may trigger an overproduction of
nitric oxide, leading to monocytes and macrophages dysfunction [2,3].
This explains the association of this disorder with many
immunodeficiency syndromes, hemophagocytic lymphohistiocytosis,
pulmonary alveolar proteinosis and renal disease seen in older untreated
patients with LPI. The elevation of LDH and ferritin in our case is also
a known feature and a biomarker, along with ammonia, in LPI.
Misdiagnosis in patients of LPI, with either milk
protein intolerance causing enterocolitis, malabsorptive syndrome or
autoimmune disorders have been reported in literature [1,5]. It is thus
important to recognize and treat the hyperammonemia early enough to be
able to prevent further neurological damage and other complications. A
close follow-up of patients is unnecessary. A bone densitometry has not
been done on follow-up for this child due to logistic reasons, but is
planned.
The standard treatment for hyperammonemia in LPI
involves low protein diet, ammonia lowering nitrogen scavengers like
sodium benzoate (100-250 mg/kg/day in 3 divided doses), carnitine (100
mg/kg/day in three divided doses) and low-dose citrulline
supplementation.
Arginine supplementation is unhelpful as oral
arginine is not absorbed from intestinal mucosa. Care has to be taken in
supplementing with citrulline as higher doses may elevate the
intracellular arginine levels paradoxically leading to harmful effects
[3].
Another Indian patient was previously reported,
suspected on clinical and biochemical grounds [6]. As LPI is an
autosomal recessive trait, parents of probands have a 25% risk of
recurrence in their subsequent pregnancies. Thus, genetic counseling is
extremely important, as it opens the possibility of prenatal diagnosis
once the disease-causing mutation is detected in the family.
Acknowledgements: Dr Renu Saxena and Molecular
genetics department, Sir Ganga Ram Hospital, and Dr I C Verma for
parental mutation analysis. Mutation analysis was part of a project
supported by the Swiss National Science Foundation (Grant
310030_153196).
Contributors: SBM: conceived, designed and wrote
the manuscript and will act as the guarantor of the study; VJ, RB:
suspected the diagnosis and facilitated diagnostic testing; GMR:
performed biochemical testing and interpretation of results. JH
performed molecular diagnosis; SBM, VJ, GMR: collected the data; VJ, RB,
SBM: managed the case and provided critical analysis of the manuscript;
VJ, GMR: contributed in manuscript writing; JH: revised the manuscript
critically for important intellectual content.
Funding: None; Competing interest: None
stated.
References
1. Sebastio G, Nunes V. Lysinuric protein
intolerance. 2006 Dec 21 [Updated 2011 Oct 13]. In: Pagon RA,
Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet].
Seattle (WA): University of Washington, Seattle; 1993-2015. Available
from: http://www.ncbi.nlm.nih.gov/books/NBK1361/. Accessed on 20
Febuary, 2016.
2. Sebastio G, Sperandeo MP, Andria G. Lysinuric
protein intolerance: Reviewing concepts on a multisystem disease. Am J
Med Genet. 2011;157:54-62.
3. Ogier de Baulny H, Schiff M, Dionisi-Vici C.
Lysinuric protein intolerance (LPI): A multi organ disease by far more
complex than a classic urea cycle disorder. Mol Genet Metab.
2012;106:12-7.
4. Palacín M, Bertran J, Chillarón J, Estévez R,
Zorzano A. Lysinuric protein intolerance mechanisms of pathophysiology.
Mol Genet Metab. 2004;81:S27-37.
5. Maines E, Comberiati P, Piacntini GL, Boner AL,
Peroni DG. Lysinuric protein intolerance can be misdiagnosed as food
protein-induced enterocolitis syndrome. Pediatr Allergy Immunol.
2013;24:509-10.
6. Moosa NV, Minal D, Rao AN, Kumar A. Recurrent
stupor due to lysinuric protein intolerance. Neurol India.
2005;53:333-4.
|
|
|
|